MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00330-025-11640-y

Медицинская библиотека · European radiology · 2025

Comparison of diffusion-weighted and contrast-enhanced MRI for monitoring response to neoadjuvant therapy in breast cancer.

Eom Hye Joung, Kim Hak Hee, Kim Hee Jeong, Choi Woo Jung, Chae Eun Young, Shin Hee Jung, Cha Joo Hee

СтатьяСравнительное исследованиеПеревод в очереди

Аннотация

OBJECTIVES

To evaluate the diagnostic performance of post-neoadjuvant therapy (NAT) diffusion-weighted magnetic resonance imaging (DW-MRI) compared to contrast-enhanced MRI (CE-MRI) in predicting tumor response in breast cancer.

MATERIALS AND

METHODS

Patients with breast cancer who were examined using 3.0-T MRI after NAT and underwent surgery between 2015 and 2018 were studied. Qualitative assessment of pathological complete response (pCR) and size of residual tumor following NAT were evaluated using CE-MRI and DW-MRI with b-values of 0 and 1000 s/mm2. Apparent diffusion coefficient (ADC) cut-off for predicting pCR was estimated using Youden's Index in lesions with residual high signal intensity. Agreement of residual tumor size at CE-MRI, DW-MRI, and pathology was compared.

RESULTS

A total of 1062 patients (49.3 years ± 9.0) were evaluated. Sensitivity for predicting pCR did not show a significant difference between CE-MRI and DW-MRI (65.3% and 62.9%, p = 0.50). The HR+/HER2- subtype showed significantly lower positive predictive value and higher negative predictive value than the others. Agreement of residual tumor size between CE-MRI and pathology (intraclass correlation coefficient [ICC], 0.62; 95% confidence interval [CI]: 0.58-0.66) and between DW-MRI and pathology (ICC, 0.64; 95% CI: 0.61-0.68) did not differ significantly (p = 0.49). Residual tumor size was underestimated in the HR+/HER2- subtype and overestimated in the HR-/HER2+ subtype. The optimum ADC cut-off was 1.22 × 10-3 mm2/s, with the area under the curve of 0.73 (95% CI: 0.68-0.78).

CONCLUSION

DW-MRI demonstrated comparable sensitivity for predicting pCR and agreement in residual invasive tumor size measurement to CE-MRI. ADC can be used as an additional tool for distinguishing residual tumors from post-treatment changes.

KEY POINTS: Question The effectiveness of diffusion-weighted MRI in predicting tumor response to NAT in breast cancer remains uncertain. Findings Diffusion-weighted MRI demonstrated similar sensitivity to CE-MRI in predicting pCR and comparable accuracy in measuring residual tumor size. Clinical relevance Diffusion-weighted MRI could potentially be used as an alternative or complementary technique to CE-MRI for evaluating tumor response to NAT in patients with breast cancer.

Для цитирования: Eom Hye Joung, Kim Hak Hee, Kim Hee Jeong, Choi Woo Jung, Chae Eun Young, Shin Hee Jung, Cha Joo Hee. Comparison of diffusion-weighted and contrast-enhanced MRI for monitoring response to neoadjuvant therapy in breast cancer.. European radiology. 2025. DOI: 10.1007/s00330-025-11640-y.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.